ESPEROVAX
Live / Applied — Second extension granted (statement of use) (as of 06 Jan 2026)
What this means for you
Not registered yet, but its 20 Dec 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98324183
- Mark type
- Stylized text
- Filed
- 20 Dec 2023
- Published for opposition
- 26 Nov 2024
- Attorney of record
- J. Matthew Buchanan
Goods and services
- Class 005 — Pharmaceuticals: Vaccines; Oral vaccines; Modified cells for medical or clinical use; yeast-based pharmaceuticals for prevention or treatment of infectious diseases; Oral vaccine preparations; Pharmaceutical products for the treatment of infectious diseases; Recombinant yeast-based pharmaceutical products for prevention or treatment of infectious diseases; Yeast-based oral vaccines; Pharmaceutical preparations, namely, a drug delivery system for oral administration of vaccines comprising yeast-based oral vaccines; Pharmaceutical products, namely, yeast-based oral vaccines; Biological and pharmaceutical preparations, namely, recombinant yeast for prevention or treatment of infectious diseases
- Class 042 — Scientific and technological services: Medical research in the field of vaccines and medicines; Research and development of vaccines and medicines; Research and development in the pharmaceutical and biotechnology fields; Scientific research in the field of vaccines and medicines; Pharmaceutical research and development; Research and development in the field of immunology; Research and development in the field of microorganisms, namely, research and development related to yeast; Research and development in the field of therapeutics; Development of pharmaceutical preparations and medicines; Scientific study and research in the field of medicine; Scientific study and research in the field of healthcare products; Medical and scientific research; Research and development of pharmaceutical and therapeutic preparations; Pharmaceutical, biologic, and vaccine research and development
Owner
- Esperovax, Inc., Plymouth, MI, US
- Esperovax, Inc., Plymouth, MI, US
Prosecution history
- 07 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 06 Jan 2026 — SOU EXTENSION 2 GRANTED
- 06 Jan 2026 — SOU EXTENSION 2 FILED
- 06 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 30 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 30 Oct 2025 — SOU EXTENSION 1 GRANTED
- 06 Jul 2025 — SOU EXTENSION 1 FILED
- 28 Oct 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 11 Aug 2025 — SOU EXTENSION RECEIVED WITH TEAS PETITION
- 11 Aug 2025 — NOTICE OF REVIVAL - E-MAILED
- 11 Aug 2025 — PETITION TO REVIVE-GRANTED
- 11 Aug 2025 — TEAS PETITION TO REVIVE RECEIVED
- 11 Aug 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 11 Aug 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 07 Jan 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT